Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Mr. C. Russell Trenary, III$186.1M
Market Cap • 15/04/20242010
(há 14 anos)
2016
(8 years ago)
NASDAQ
Listagem
Iselin
Sede • New Jersey17
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
OTLKSó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.